老年乳腺癌患者心脏毒性
Kalliopi Keramida1,2, Anastasia Constantinidou3,4, Dorothea Tsekoura5
12nd Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Athens University Hospital Attikon, 11527 Athens, Greece.
Cancers
|July 12, 2025
概括
老年乳腺癌患者因治疗而面临显著的心脏毒性风险. 综合评估和量身定制的策略对于管理癌症和心血管健康在这个人群中至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
背景情况:
- 心脏毒性是老年乳腺癌 (BC) 患者的主要死亡原因.
- 在老年人中治疗BC是复杂的,因为在临床试验中异质性和代表性不足.
研究的目的:
- 突出对老年患者乳腺癌管理的挑战和必要考虑,重点关注心脏毒性.
- 强调需要采用多学科方法,整合老年诊断和心血管风险评估.
主要方法:
- 对老年乳腺癌治疗当前挑战的审查.
- 对这些人口中导致心脏毒性的因素的分析.
- 讨论全面的决策策略.
主要成果:
- 乳腺癌治疗可以诱导一系列心血管疾病,包括心力衰竭,高血压和心律失常.
- 心脏毒性风险受到抗癌疗法,多药,并发症,虚弱和遗传因素的影响.
结论:
- 一个整体的方法是必不可少的,考虑到BC的特点,患者的健康,脆弱和心脏毒性风险.
- 除了患者教育,预防性瘤和心脏瘤策略至关重要.
- 迫切需要针对老年乳腺癌患者进行前性临床试验.
相关概念视频
Heart Failure Drugs: Inotropic Agents
733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733
Cardiomyopathy V: Interprofessional Care
37
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
37
Cardiomyopathy VI: Nursing Management
47
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
47
Cardiomyopathy II: Dilated Cardiomyopathy
24
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
24
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513


